Background: Diagnosis of childhood tuberculosis (TB) is difficult in high TB burden settings. Interferon-gamma-induced protein 10 (IP10) has been suggested as a marker of TB infection and disease, but its ability to differentiate the two conditions remains uncertain.
Introduction
One of the most significant barriers for the appropriate management of Tuberculosis (TB) is the lack of suitable diagnostic tests. This problem is especially critical in settings where facilities are limited and other infections with overlapping clinical presentation are highly prevalent. Childhood TB presentation differs from adult TB as children experience more extra-pulmonary TB (EPTB) and lung involvement is frequently disseminated and without cavitations. Young children are unable to expectorate sputum and the specimens collected, such as gastric aspirates, are often paucibacillary and sometimes contain test inhibitors. Most diagnostics for TB thus perform poorly in children [1, 2] and new tests or markers to diagnose TB in children are needed.
Interferon-gamma (INFc) release assays (IGRAs) were developed in the last decade and are reported to have comparable sensitivity and higher specificity than the Tuberculin Skin Test (TST) to identify latent TB infections (LTBI). Their performance however is less reliable in young children and in patients co-infected with the Human Immunodeficiency Virus (HIV) [3, 4, 5] . These assays are frequently used by clinicians to support a diagnosis of symptomatic TB [3, 6, 7] , even though they cannot distinguish between LTBI and symptomatic disease. IGRAS are also increasingly used in high TB incidence settings, despite the limited information of their performance in these locations [8, 9, 10] .
INFc-induced protein 10 (IP10, also known as Chemokine (C-X-C motif) ligand 10 or CXCL10) is another biomarker recently reported to identify LTBI, which, when combined with IGRAS is said to increase the sensitivity of the assays [10] . IP10 expression is putatively less affected by HIV [11] and young age [12, 13] and it is said to have potential to differentiate between LTBI and symptomatic infections [12, 14] .
We have thus conducted a study in Southern Ethiopia to describe INFc and IP10 concentrations of children presenting with symptoms compatible with TB, asymptomatic children in contact with adults with smear-positive pulmonary TB (PTB) and asymptomatic community controls to explore whether INFc or IP10 can distinguish between symptomatic and asymptomatic infections in a high TB burden setting and assess whether these markers could be used to support the diagnosis of children with symptoms of TB.
Materials and Methods
This was a cross sectional study of 1 to 15 year old children with symptoms suggestive of TB, children in contact with adults with smear-positive PTB and community controls without known contact with TB. The study was based in Awassa, in the Southern Region of Ethiopia, which has a population of over 15 million.
Children with symptoms of TB (called symptomatics) were enrolled consecutively at three health service providers (Awassa Health Centre, Bushullo Major Health Centre and University of Hawassa referral hospital). These included consecutive children with cough or fever for more than 2 weeks, night sweats, anorexia, weight loss, failure to thrive or non-specific symptoms in the presence of a history of contact with an adult with PTB. Children were invited to participate at the time of presentation to the clinic. All children underwent a clinical examination, chest X-rays, TST, three sputum or gastric lavage examinations and fine needle aspiration if enlarged lymph nodes were detected. All specimens were examined using light smear microscopy and culture on Lowenstein Jensen media and children were classified as having confirmed (positive smear microscopy or culture), probable (negative smear microscopy and culture, clinical and radiological findings consistent with TB, no improvement after a full course of antibiotics and the clinician initiating anti-TB treatment) or unlikely TB (children with alternative diagnosis or clinical improvement after a course of broad spectrum antibiotics).
In addition, contact children 1-15 year old residing with adults with smear-positive PTB (called contacts) were enrolled by identifying adults attending the same study centres with a history of cough for more than 2 weeks duration who had sputum smearpositive PTB. Once a smear-positive adult had been identified, study investigators inquired whether they had children at home and visited the households if the family resided within a 20 km radius from Awassa. All children living under a single roof who shared meal times with the adult were invited to participate after obtaining informed parental consent, unless they had previously received treatment for TB. All children who shared meals at home with the index cases were included, regardless of the duration of contact.
Community controls were defined as children residing in the community who did not have a known contact with adults with PTB. Controls were selected from Awassa and surrounding kebeles, which are the smallest administrative units of Ethiopia and comprise at least five hundred families or 3,500 to 5,000 inhabitants. A list of all villages and kebeles located within a 20 Km radius from Awassa was constructed. Controls were enrolled from villages adjacent to the villages where contacts resided. We enrolled more controls from rural villages than from urban areas as the risk of TB transmission from casual contact could be higher among urban residents. Households within a village were selected by spinning a pen in a street somewhere between the centre and the edge of the village and children were enrolled after obtaining informed parental consent. Households were excluded if the parent indicated the family had been in contact with an adult with cough for more than 2 weeks duration in the previous 2 years or if a family member had received treatment for TB. All children were applied a TST using 2 units of Purified Protein Derivate (PPD, RT 23, Statens Serum Institute, Copenhagen, Denmark) using the Mantoux method and indurations were measured using the palpation method 48 to 72 hours later. TST results were graded as negative (,5 mm), intermediate ($5 and ,10 mm) and positive ($10 mm). Any child with signs and symptoms suggestive of TB was investigated for disease activity and treated. Contact children ,6 years old were offered INH prophylaxis for 6 months independently of their TST result, following Ethiopian TB Control Programme guidelines.
INFc and IP10 concentrations were assayed using commercially available Enzyme Linked Immunoassay (ELISA) kits. INFc was measured using the QuantiFERON-TB Gold In-Tube (QFT-IT) test (Cellestis, Victoria, Australia). Blood samples for QFT-IT were collected in 3 tubes, one containing the Mycobacterium tuberculosis ESAT-6, CFP10 and TB7-7 antigens; one with non-specific mytogen (phytohemoagglutinin) to serve as positive control and one blank tube (nil) to serve as negative control. The three tubes were incubated at 37u for 16-24 hours. Supernatant plasma was harvested after centrifugation to separate the blood cells and stored at 270uC. INFc was measured using the manufacturer's ELISA in a Bio-Rad Plate reader (Model n 550) and read at 450 nm. IGRAs were classified as positive, negative or indeterminate using the manufacturer's software. IP10 concentrations were measured in the same supernatant using a Human IP10 ELISA Construction Kit (Antigenix America Inc, New York, NY). HIV infections were established using two blood-based ELISA methods.
Means and standard deviations (SD) or medians and interquartile ranges (IQR) were used to describe continuous variables. Parametric tests and non parametric tests were used to compare means and medians. The proportion of children in each study category with positive/negative tests compared using Chi-Square and Fisher's exact tests (if expected values were less than,5) and the agreement between TST and INFc was described using Kappa statistics. IP10 concentrations were described using boxplots stratified by TST and INFc concordance. The sample size calculations took into account the feasibility to visit about 200 households (of index cases) within the available time and resources and that each household had an average of two children ,5 years old and it was expected that 200 children with signs and sypmtoms of TB would attend the health services. It was expected that 50% of the participants would be TST positive and 70% and 30%, of TST-positive children would be INF-c positive and negative, respectively. It was also assumed that 30% and 70% of TSTnegative children would be INF-c positive and negative, respectively. This sample size would allow estimating the proportion of children with positive and negative INF-c results by study group with a precision of 67%. Sample size calculation for the comparison of quantitative data (i.e. differences in IP-10 concentrations by study group) would have required prior information of the dispersion of IP-10 concentrations to estimate standard deviations or medians. As this information was not available, this study should be considered ''exploratory'', as it might not have enough power for the differences reported. The ability of IP10 to discriminate between children with and without TB infection or disease was evaluated using Receiver Operating Characteristic (ROC) curves using Prism 5 software (GraphPad PRISM, version 5). ROC curves were constructed with children with confirmed TB and controls and contact children with TST+/INFc+ and controls. Only controls with TST-/INFc-results were included in the ROC analysis to select children unlikely to have TB infection. The area under the curve (AUC) for both confirmed and contact children were compared to ascertain whether IP10 could discriminate between the two conditions. Statistical tests were considered significant if p values were ,0.05.
The study protocol was approved by the Health Bureau of the Southern Region and the Research Ethics Committees of the Liverpool School of Tropical Medicine, Hawassa University and the Sciences and Technology Commission of Ethiopia. The study protocol was registered in the clinicatrials.gov clinical trials register (registration number NCT00456469)
Results
Eight hundred thirteen, 322 symptomatic, 335 contact and 156 control children were enrolled. The flow chart of the three groups is described in Figure 1 . Twenty eight (8.7%) of 322 symptomatic children had confirmed, 136 (42.2%) probable and 131 (40.7%) unlikely TB and 27 were excluded because a definitive diagnosis was not reached or the child left the hospital before completing the investigations. The 335 contact children were recruited from 125 adult index cases who had ''scanty'' (18, 5.5%), ''+'' (188, 57%), ''++'' (109, 33%) or ''+++'' (15, 4.5%) smear microscopy grades in their sputum smear examination. In five contacts the smear result of the adult was not recorded. The median contact duration was 10 hours per week (range of 1 to 41 hours). The characteristics of the participants are shown in Table 1 . Children with probable TB were more likely to be male (67.6%), while children in the other groups had similar proportions of males and females. Children had similar median age with symptomatic and control children having a median age of 6 years and contacts having a median of 8 years. Although the proportion of children reporting to have received BCG was similar across the groups, BCG scars were found less frequently in children with confirmed and probable TB (p,0.001). HIV was positive in none of the children with confirmed TB, 14 (10.9%) children with probable and 8 (6.5%) unlikely TB cases, 27 (8.2%) contacts and 3 (1.9%) controls (p = 0.005). The number of residents per household was higher among children with symptoms IP10 concentrations are shown in Figure 2 . Stimulated concentrations were much higher than non-stimulated concentrations in all groups (p,0.001). Non-stimulated concentrations were highest in children with confirmed TB and lowest in controls (medians 1606 and 386 pg/ml). Stimulated concentrations were higher in children with confirmed TB and contacts (7812 and 5616 pg/ml, respectively) than in children with probable and unlikely TB (3680 and 2532 pg/ml, respectively, Kruskal-Wallis, p = 0.02). The difference of stimulated minus non-stimulated concentrations are shown in Table 3 by TST and INFc results and study group. Among patients with positive TST, symptomatic and contact children had higher IP10 concentrations than controls (p = 0.03 and p,0.001, respectively). Among children with negative TST, children with confirmed TB and contacts had higher IP10 concentrations than controls (p = 0.02 and p = 0.001, respectively. There was no difference in the IP10 concentrations across study groups among children with INFc2 results, while contact children with INFc+ results had the highest IP10 concentrations, followed by symptomatic and control children. Median (IQR) IP10 concentrations (stimulated minus non-stimulated) are shown in Figure 3 IP10 concentrations than children without HIV across all study groups (p.0.1) as shown in Figure 4 . IP10 concentrations of children with confirmed TB (N = 22, median IP10 7774 pg/ml) and contacts with TST+ and/or INFc+ (N = 148, median IP10 12490 pg/ml) where compared against controls with TST2 and INFc2 (N = 86, median IP10 704 pg/ml) to construct the ROC curves, as shown in Figure 5 . The ROC curves for both confirmed and contact children had the same shape, with cut-off points for best performance being 3128 pg/ml (sensitivity 81.8%, 95%CI = 59.7-94.8, specificity 96.5% 95%CI 90.1-99.3 and area under the curve (AUC) of 0.87%, 95%CI 0.75-0.99) for confirmed TB and 3022 pg/ml (sensitivity 77%, 95%CI 69.4-83.5%, specificity 96.5%, 95%CI 90.14-99.3%, and an AUC of 0.87, 95%CI 0.82-0.92) for contacts.
Discussion
Despite significant research efforts and technological breakthroughs to develop new diagnostics for TB [15] , current diagnostic tests have lower sensitivity in children than in adults [1, 2] . New diagnostics are needed to identify children with TB and to differentiate between latent and active TB in high incidence settings with limited resources.
Despite a large body of evidence of the performance characteristics of IGRAs for the diagnosis of LTBI and the identification of individuals infected during TB outbreaks in low TB incidence settings [6, 16, 17, 18, 19] , there is a small number of studies assessing the IGRAS performance and their utility in high incidence countries [20, 21, 22] . The data presented here therefore represents a rare opportunity to compare TST, INFc and IP10 in children with different degrees of exposure to infection and certainty of diagnosis residing in a high TB burden setting.
An important difference to reports from industrialized countries was the high proportion of QFT-IT tests with indeterminate results. Other studies from Africa have reported high rates of indeterminate results [23] , and the reason for this high frequency remains unexplained. Our team has conducted similar studies in Nigeria [24] , Nepal [8] and Yemen, took care to re-stock tests frequently and used high altitude control tubes provided by the manufacturer. Most indeterminate results however were due to failure of the positive control and further studies are needed to explore whether this was due to a loss of test integrity or an unidentified background morbidity such as parasitic, bacterial or viral infections [25] . The interpretation of the data is also hampered by the lack of reference standards for LTBI. The data however confirms that INFc, as TST, are more likely to be positive in children with contact or confirmed TB than in controls.
Neither INFc nor TST differentiate between active and latent infections and thus their diagnostic value is restricted to the confirmation of a history of infection [3, 19, 26] . Given that a number of children had discrepant INFc/TST results, cost and logistic constrains aside, the use of both TST and INFc would identify a higher number of children with evidence of infection than a single test alone. This study also describes IP10 concentrations of children at different risk of infection, and how these concentrations vary with TST, INFc and HIV. IP10 is a cytokine expressed in response to IFNc stimulation by cell types involved in delayed-type hypersensitivity [27] , including lymphocytes, monocytes, endothelial cells and fibroblasts and is a chemo-attractant to monocytes and activated Th1 lymphocytes [28] , promoting selective enhancement of Th1 responses and increasing IFN-c gene expression [29] . Recent studies have reported that IP10 expression is enhanced in individuals with active TB [30, 31] and latent infection [12, 13, 32] and that combined with INFc could increase the sensitivity of the IGRAS [9, 12] . Although some reports have suggested that this marker could differentiate between active and latent infection [14, 33] , not all studies have replicated these observations [10, 14] .
IP-10 concentrations were higher among children with confirmed TB and contacts, with the highest concentrations observed in contact children, which is in agreement with recently recent reports from low incidence settings [12, 14] . IP10 concentrations were generally higher among children with INFc+ results and there was no difference in the median concentrations of children with and without HIV infection. This latter characteristic could have practical applications, increasing the sensitivity of INFc based tests in areas of high HIV prevalence. Interestingly, non-stimulated IP10 concentrations were higher in children with confirmed TB, resulting in a smaller difference between stimulated and non-stimulated concentrations. Although non-specific IP10 increases have been described in acute and chronic diseases other than TB [34, 35, 36, 37] , these findings suggest that IP10 expression may vary during the course of disease progression, maybe with higher expression during the primary stages of granuloma formation, which involves the recruitment of monocytes and Th1 gammadelta T-cells [38] and lower expression in the presence of progressive unchecked infections, in the presence of immunosuppression, as described for INFc.
The ROC curve analysis however suggested that the cut offs with best test performance to differentiate children with confirmed TB and controls was similar to the cut offs to differentiate contacts and controls, with similar AUC. Thus, similar to INFc and TST, IP10 differentiated between infected and non-infected children but is unable to differentiate between latent and active TB. Data from children residing in a high burden areas is scarce and the sensitivity of 81.8% obtained is lower than reported from Indian adults [10] in Chennai (92.5%, 95%CI: 88.6%-96.4%), which also reported a lower specificity (48%). Ruhwald et. al. [39] selected a cut off of 673 pg/ml for Danish adolescents and adults and Lighter et. al [12] selected a cut off of 732 pg/ml for USA children. Applying Ruhwald et. al., cut off to Ethiopia would increase the sensitivity to 86% and reduce the specificity to 48%, which is similar to those reported by Kabeer et al in India, suggesting that there is more agreement of test performance across settings than suggested by these reports.
This study therefore describes INFc and IP10 expression in children at different risk of infection and disease in a country with a high incidence of TB. Children with probable TB had different tests results patterns than children with confirmed TB as the former had more TST but less INFc positive results, thus reflecting the heterogeneity of this group and underscoring the importance of using clear reporting group categories based on the certainty of diagnosis to facilitate the interpretation of data.
Our findings therefore demonstrate that both INFc and IP10 identify children with latent and active TB. IP10 is less affected by the presence of HIV co-infection than INFc and has the potential to increase the sensitivity of the IGRAS when used in combination with INFc. INFc, IP10 and TST however are unable to differentiate between latent and active disease.
Longitudinal studies to describe the natural variation of these markers over time and their ability to identify children with latent infections at risk of disease progression or children at risk of poor treatment response after initiation of anti-TB therapy are needed. However, given the high cost of the IGRAS and the high proportion of indeterminate results obtained, control programmes should refrain from incorporating these tests until clear advantages over the TST are demonstrated. 
